We stimulated primary SFs from six patients with RA with a combination of three disease-relevant cytokines (TNF-α, IL-1β, and interferon [IFN]-γ) and treated these with three types of JAKis (tofacitinib, baricitinib or upadacitinib) or a TNFi (adalimumab). This evidence concerns the gene TNF and rheumatoid arthritis.